Marie-Christine Jones

Dr. Marie-Christine Jones

School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
MJMarie-Christine Jones
Marie-Christine Jones
JLJean-Christophe Leroux
Jean-Christophe Leroux

1 October 2010 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
GGGeneviève Gaucher
Geneviève Gaucher
PSPrashant Satturwar
Prashant Satturwar
MJMarie-Christine Jones
Marie-Christine Jones
AFAlexandra Furtos
Alexandra Furtos
JLJean-Christophe Leroux
Jean-Christophe Leroux

21 June 2003 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MJMarie-Christine Jones
Marie-Christine Jones
MRMaxime Ranger
Maxime Ranger
JLJean-Christophe Leroux
Jean-Christophe Leroux

1 January 2000 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
JTJ. Taillefer
J. Taillefer
MJMarie-Christine Jones
Marie-Christine Jones
NBN. Brasseur
N. Brasseur
JLJ.E. van Lier
J.E. van Lier
JLJ.‐C. Leroux
J.‐C. Leroux

15 September 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
KMKenny Man
Kenny Man
MBMathieu Y. Brunet
Mathieu Y. Brunet
MJMarie-Christine Jones
Marie-Christine Jones
SCSophie Cox
Sophie Cox
Extracellular vesicles (EVs) are emerging as promising nanoscale therapeutics due to their intrinsic role as mediators of intercellular communication, regulating tissue development and homeostasis. The low immunogenicity and natural cell-targeting capabilities of EVs has led to extensive research investigating their potential as novel acellular tools for tissue regeneration or for the diagnosis of pathological conditions. However, the clinical use of EVs has been hindered by issues with yield and heterogeneity. From the modification of parental cells and naturally-derived vesicles to the development of artificial biomimetic nanoparticles or the functionalisation of biomaterials, a multitude of techniques have been employed to augment EVs therapeutic efficacy. This review will explore various engineering strategies that could promote EVs scalability and therapeutic effectiveness beyond their native utility. Herein, we highlight the current state-of-the-art EV-engineering techniques with discussion of opportunities and obstacles for each. This is synthesised into a guide for selecting a suitable strategy to maximise the potential efficacy of EVs as nanoscale therapeutics.

1 June 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
MJMarie-Christine Jones
Marie-Christine Jones
SJStuart A. Jones
Stuart A. Jones
YRYanira Riffo-Vasquez
Yanira Riffo-Vasquez
DSDomenico Spina
Domenico Spina
EHEwelina Hoffman
Ewelina Hoffman
LDLea Ann Dailey
Lea Ann Dailey